美国联合医疗公司宣布，其Uheart异种心脏移植项目已获得美国食品药品监督管理局的批准，即将进入临床试验阶段。这一关键监管许可标志着该公司在利用基因编辑猪心脏解决人类器官短缺难题的道路上迈出了实质性一步。
异种移植领域长期面临免疫排斥和安全性的重大挑战，而此次获批的临床试验旨在评估Uheart生物人工心脏的可行性与耐受性。该产品采用了多重基因编辑技术，旨在最大程度降低人体免疫系统的排异反应，并为终末期心衰患者提供一种潜在的长期解决方案。
若后续临床试验进展顺利，这项技术有望革新器官移植的现有格局，为数以万计等待心脏移植的患者带来新的希望。行业观察人士指出，此次FDA开绿灯，不仅是对美国联合医疗技术路线的认可，也可能为整个异种移植领域的研发注入新的动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.